AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators -- Company expands leadership team with CMO Philippe Wiesel, CBO Paul van der Horst and CFO Tolga Hassan -- AgomAb Therapeutics N.V. announced today the closing of a $74 million Series B financing round led by Redmile Group, with participation from Cormorant Asset Management. All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures. The proceeds of the Series B will be...
Source: finanznachrichten.de